The EPS miss is negligible. The stock will be driven by upcoming catalysts: complete Phase 1/2 lupus/scleroderma data at EULAR (June 3-6) and initial PC-free lupus data expected in 1H26. The $150M financing removes near-term dilution risk. Monitor EULAR presentations for signs of efficacy and safety that could de-risk the pivotal program.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 14 $3.61entry
- T+1 · 6mo ago −8.31%α −7.08% · $3.31
- T+5 · 6mo ago +2.22%α +2.93% · $3.69
- T+20 · 5mo ago −16.62%α −15.76% · $3.01
- T+60 · 3mo ago −22.44%α −26.03% · $2.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cabaletta Bio reported Q1 2026 EPS of -$0.40, a 3.1% miss vs consensus of -$0.39, with no revenue. The miss is marginal and typical for a pre-commercial biotech. The key positive is the $150M oversubscribed financing closed in May 2026, extending the cash runway into mid-2027, and encouraging PC-free clinical data from the RESET-PV study presented at ASGCT. The stock is likely to trade on pipeline catalysts (EULAR data in June, lupus data in 2H26) rather than the minor EPS miss.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.40 vs consensus -$0.39 (3.1% miss)
- No revenue reported (pre-commercial stage)
- Cash, cash equivalents and short-term investments of $116.6M as of March 31, 2026
- Closed $150M registered direct offering in May 2026, extending cash runway into mid-2027
- PC-free clinical data from lowest-dose RESET-PV cohort presented at ASGCT 2026 showing compelling drug-free responses in half of patients at 6 months
- Complete Phase 1/2 lupus and scleroderma data to be presented at EULAR Congress June 3-6, 2026
- Pivotal RESET-Myositis cohort progressing toward first BLA submission planned for 2027
- 10-year commercial supply agreement with Cellares for automated manufacturing
Financial Impact
EPS miss of $0.01 per share is immaterial for a pre-revenue biotech; $150M capital raise is the dominant financial event
Risk Factors
- Clinical trial failure or disappointing efficacy/safety data at EULAR or in upcoming PC-free cohorts
- Regulatory delays or negative FDA feedback on BLA pathway for myositis
- Cash burn rate may require additional financing before mid-2027 if milestones slip
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294776 |
Track record
29 reports on CABA
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers